SCHEMBL903555

SCHEMBL903555

O=C1N[C@H]2[C@H](CS[C@H]2CCCCCOCCCCCC(=O)ON2C(=O)CCC2=O)N1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.61
▸ PKM P14618 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ ABL1 P00519 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ IDE P14735 1/20 0.57
▸ MAPK1 P28482 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ RIN1 Q13671 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ HLCS P50747 6/20 0.53
▸ F2 P00734 1/20 0.47
▸ PRSS1 P07477 1/20 0.47
▸ PRSS2 P07478 1/20 0.47
▸ PRSS3 P35030 1/20 0.47
▸ TPSAB1 Q15661 1/20 0.47
▸ PLCD1 P51178 1/20 0.44
▸ HPSE Q9Y251 1/20 0.44
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10029433 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL3431980 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL12010938 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL81912 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL17170012 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL24131520 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL13065000 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL12424059 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL19627566 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA
SCHEMBL16625034 0.94 TDP1 (0.69) TDP1PKMMEN1ABL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2013-07-25 — — US disclosed
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2013-07-25 — — US disclosed
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2013-07-25 — — US disclosed
WO-2012042123-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY SANOFI (FR) 2012-04-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190268-A1 BIOTINYLATED POLYSACCHARIDES HAVING AN ANTITHROMBOTIC ACTIVITY AND IMPROVED METABOLIC STABILITY BTD, FGB, F13B TDP1 4155/4885PKM 3797/4885MEN1 3269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback